VK2735 shows strong early weight loss data, positioning Viking Therapeutics as a potential third major player in the booming GLP-1 obesity drug market. Learn more on VKTX stock here.

A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

Joie Armstrong asked her doctor about taking a GLP-1 medication to help her lose weight six times before she got a prescription, and then was denied coverage by her insurance company. Adrian, a ...

The Delhi High Court on Tuesday disposed of a public interest litigation (PIL) raising alarm over the off-label and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street ...